Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- Senior battling leukemia embodies Mona Shores football’s fighting spirit, will join team at Ford Fieldon January 20, 2021 at 9:36 am
Devin Gibbs, who was diagnosed with Acute Myeloid Leukemia early this season, to be on sideline with Sailors for Friday’s state finals game.
- Sheet drive for pediatric cancer patients underwayon January 20, 2021 at 7:30 am
Donated sheets are then given to kids admitted for pediatric cancer treatments. "We generally ask for sheets that are very soft in material - the fleece, the flannel -- because these kids tend to have ...
- Combination Therapy May Help Treat Acute Myeloid Leukemiaon January 20, 2021 at 7:23 am
Synergistic effect of two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used as single-agent therapy.
- TBI Plus Etoposide Prior to HSCT Leads to Improved OS, Lower Relapse Risk in High-Risk Pediatric ALLon January 19, 2021 at 9:18 am
Based on recent study results, investigators recommended TBI plus etoposide for patients older than 4 years of age with high-risk ALL undergoing allogeneic hematopoietic stem cell transplantation.
- Henderson community rallies together to show support for teen recently diagnosed with leukemiaon January 19, 2021 at 7:32 am
Addison Graham returned to Henderson Monday night after a weekend of treatment at a Dallas hospital. The community gathered on Main Street to welcome her home.
- Community rallies behind Valley teen battling leukemiaon January 18, 2021 at 4:34 pm
During a time when so many people are struggling due to the pandemic, one Valley family and their daughter’s positive diagnosis has led to another health battle.
- Mahopac baseball team 'adopts' 16-year-old battling leukemiaon January 14, 2021 at 9:28 am
The Mahopac baseball team partnered with Friends of Jaclyn, a nonprofit that matches teams with children battling cancer.
- Leukemia Therapeutics Market- Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2028on January 14, 2021 at 4:33 am
Research Nester has released a report titled " Leukemia Therapeutics Market - Global Demand Analysis & Opportunity Outlook 2028" which also includes some of the prominent market analyzing parameters ...
- Seymour native nominated for Leukemia and Lymphoma Society 2021 Man of the Yearon January 12, 2021 at 11:18 pm
Being a pediatric cancer patient when he was a teenager, Iman Tucker said his memory fades with what he faced. In December 2008 at age 14, the Seymour native was diagnosed with Burkitt lymphoma, an ...
- ‘NO MO CHEMO’: Family celebrates end of 5-year-old’s leukemia treatments with massive car paradeon January 9, 2021 at 7:17 pm
Charlotte Block was diagnosed with acute lymphocytic leukemia just two weeks shy of her third birthday. Now, she’s able to celebrate the end of her treatments with the entire community.
via Bing News